Role of Academic Drug Discovery in the Quest for New CNS Therapeutics

Brian H. Yokley, Matthew Hartman, Barbara S. Slusher

Research output: Contribution to journalReview articlepeer-review

Abstract

There was a greater than 50% decline in central nervous system (CNS) drug discovery and development programs by major pharmaceutical companies from 2009 to 2014. This decline was paralleled by a rise in the number of university led drug discovery centers, many in the CNS area, and a growth in the number of public-private drug discovery partnerships. Diverse operating models have emerged as the academic drug discovery centers adapt to this changing ecosystem.

Original languageEnglish (US)
Pages (from-to)429-431
Number of pages3
JournalACS Chemical Neuroscience
Volume8
Issue number3
DOIs
StatePublished - Mar 15 2017

Keywords

  • Academic drug discovery
  • public-private partnerships

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'Role of Academic Drug Discovery in the Quest for New CNS Therapeutics'. Together they form a unique fingerprint.

Cite this